12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Company News  |  Deals

QRxPharma, Actavis deal

QRxPharma granted Actavis' Actavis Inc. subsidiary exclusive rights to commercialize pain product...

Read the full 49 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >